miRNA cDNA合成試劑盒 | 貨號 G269/G270

產品介紹: miRNA cDNA合成試劑盒是從total RNA模板中有效合成第一鏈miRNA的完整系統。該試劑盒利用最佳化之突變重組M-MuLV逆轉錄酶，有效limited  RNA酶H活性。試劑盒提供的重組RNasin™核糖核酸酶抑制劑, 可有效保護RNA模板免於降解。除了基本的miRNA cDNA合成試劑盒（G269 / G270）外，客戶還可以選擇帶有Poly（A）Polymerase Tailing（G902 / G903）的miRNA cDNA合成試劑盒。 abm的miRNA cDNA合成試劑盒的兩種版本都與oligo d（T）銜接頭一起，它們選擇性到poly（A）尾部的miRNA上。包含在miRNA分析試劑盒（MA003，MA004）中的通用反向引物含有銜接子序列，因此它們必須用於由abm的miRNA cDNA合成試劑盒產生的cDNA。 miRNA的第一條cDNA可直接作為模板用於給定樣品中miRNA表達的基於qPCR的分析。 abm也具有用於所有已知miRNA序列的miRNA引物的完整文庫。更多資料請按此 miRNA primer 

Product	Description	Cat No.
miRNA cDNA Synthesis Kit	25 reactions	G269
miRNA cDNA Synthesis Kit	100 reactions	G270
miRNA cDNA Synthesis Kit, with Poly(A) Polymerase Tailing	25 reactions	G902
miRNA cDNA Synthesis Kit, with Poly(A) Polymerase Tailing	100 reactions	G903

Lang, B et al. “miR-486 functions as a tumor suppressor in esophageal cancer by targeting CDK4/BCAS2.” Oncology Reports 39:71-80 (2018). DOI: 10.3892/or.2017.6064.

Kawakubo-Yasukochi, T et al. “miR-200c-3p spreads invasive capacity in human oral squamous cell carcinoma microenvironment.” Molecular Carcinogenesis 57 (2):295-302 (2018). DOI: 10.1002/mc.22744.

Qin, X et al. “Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway.” J. Exp. Clin. Cancer Res. 148: (2017). DOI: 10.1186/s13046-017-0618-x.

Application: PCR.Shen, C et al. “Comparative analysis of cadmium responsive microRNAs in roots of two Ipomoea aquatica Forsk. cultivars with different cadmium accumulation capacities.” Plant Physiology and Biochemistry 111:329-339 (2017). DOI: 10.1016/j.plaphy.2016.12.013.

Cheng, F et al. “RNA-Binding Protein Dnd1 Promotes Breast Cancer Apoptosis by Stabilizing the Bim mRNA in a miR-221 Binding Site.” BioMed Research International : (2017). DOI: 10.1155/2017/9596152.

Wu, L et al. “Clinical significance of C/D box small nucleolar RNA U76 as an oncogene and a prognostic biomarker in hepatocellular carcinoma.” Clin Res Hepatol Gastroenterol : (2017). PubMed: 10.1016/j.clinre.2017.04.018.

Ramraj, et al. “Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease.” Oncotarget 7.14:18605 (2016). DOI: 10.18632/oncotarget.7615. Application: miRNA qPCR Analysis.